DRTS logo

ALPHA TAU MEDICAL LTD

DRTSNASDAQ
🏆 #2271 by market capEarnings Nov 19US Equity
$15.20▲ $0.16 (+1.03%)
After hours · at close
🔔
Track DRTS
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 1.0%
7d▲ 0.4%
14d▲ 2.4%
30d▲ 3.7%
ytd▲ 208.6%
1y▲ 258.5%
🏦Market Cap
$1.37B
Small Cap
📈Revenue Growth (YoY)
+0.0%
Slowing
📊Gross Margin
0.0%
Thin
💵FCF Margin
0.0%
Thin
⚖️P/S Ratio
0.0x
Cheap
Otter Score
52
Weak

Trading Snapshot

Day Range
$15.05 – $15.37
52-Week Range
$3.43 – $15.79
Volume
$3.37B
Avg Volume
$4.43B
Shares Outstanding
90.3M
Next Earnings
Dec 1, 2026

Fundamentals Snapshot

Annual Revenue
$174M
Last Q Revenue
$46M
P/E Ratio
-14.5
P/S Ratio
0.0x
EPS (TTM)
$-1.02
Dividend Yield
0.00%
Dilution (1yr)
+22.2%

Why Investors Own DRTS

  • ✓High-growth profile — revenue up +13.3% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 67% gross margin and 17% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

DRTS logo

ALPHA TAU MEDICAL LTD

DRTS
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$42M▲ +17.3% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$33M▲ +48.7% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
85.7M▲ +22.2% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
−$2M▼ −$3M YoY
StockOtter · stockotter.space

About ALPHA TAU MEDICAL LTD

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical clinical studies for mouse tumors and human-derived tumors. The company is headquartered in Jerusalem, Israel.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Weak
52/100

Analyst Price Target

ⓘ
Average Target
$18.68
▲ +22.9% Upside
High Target$22.37
Low Target$17.01
Based on 32 analysts

Latest News & Updates

🚀
Bloomberg·2h ago

ALPHA TAU MEDICAL LTD tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
CNBC·5h ago

Analysts lift DRTS price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Barron’s·1d ago

ALPHA TAU MEDICAL LTD announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.